Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Akorn, Hi-Tech Pharmacal deal

Akorn will acquire generics company Hi-Tech for $640 million in cash, or $43.50 per Hi-Tech share. The price is

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE